Table 1. Baseline demographics and disease characteristics.
| Group A (n=30), tenofovir+glycyrrhizin | Group B (n=30), tenofovir | |
| Age (years) | 49.1±12.8 | 45.3±13.3 |
| Male gender, n (%) | 23 (77) | 23 (77) |
| DM, n (%) | 2 (7) | 5 (17) |
| Hypertension, n (%) | 7 (23) | 5 (17) |
| NUC-naïve, n (%) | 24 (80) | 28 (93) |
| Cirrhosis, n (%) | 2 (7) | 4 (13) |
| Liver stiffness (kPa) | 28.7±20.4 | 30.6±15.5 |
| AST (U/l) | 1,033±932 | 848±588 |
| ALT (U/l) | 1,446±999 | 1,292±796 |
| Total bilirubin (mg/dl) | 7.8±6.0 | 9.4±8.3 |
| Creatinine (mg/dl) | 0.7±0.2 | 0.8±0.3 |
| Sodium (mmol/l) | 137.4±3.1 | 137.2±3.4 |
| Albumin (g/dl) | 3.6±0.6 | 3.6±0.5 |
| INR | 1.5±0.6 | 1.5±0.6 |
| MELD score | 16.7±6.0 | 17.4±6.1 |
| Platelet (109/l) | 160±91 | 162±68 |
| Lactate (mg/dl) | 13.7±6.2 | 21.5±33.3 |
| HBeAg positive, n (%) | 10 (33) | 12 (40) |
| Log HBV-DNA (IU/ml) | 5.9±1.7 | 6.2±1.5 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DM, diabetes mellitus; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; INR, international normalized ratio of prothrombin time; MELD, model for end-stage liver disease; NUC, nucleos(t)ide analogs.
Data are expressed as mean±s.d. or number (percentage).